US20090304828A1 - Pharmaceutical Composition and Functional Food for Suppressing and Relieving Itching and Inflammation - Google Patents

Pharmaceutical Composition and Functional Food for Suppressing and Relieving Itching and Inflammation Download PDF

Info

Publication number
US20090304828A1
US20090304828A1 US12/224,193 US22419307A US2009304828A1 US 20090304828 A1 US20090304828 A1 US 20090304828A1 US 22419307 A US22419307 A US 22419307A US 2009304828 A1 US2009304828 A1 US 2009304828A1
Authority
US
United States
Prior art keywords
citrus
inflammation
group
pharmaceutical composition
pruritus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/224,193
Inventor
Kazue Taguchi
Shigeru Taguchi
Yutaka Sashida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ERINA Co Inc
KANDS R&D CORP
Original Assignee
KANDS R&D CORP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KANDS R&D CORP filed Critical KANDS R&D CORP
Assigned to KANDS R&D CORPORATION, ERINA CO., INC. reassignment KANDS R&D CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SASHIDA, YUTAKA, TAGUCHI, KAZUE, TAGUCHI, SHIGERU
Publication of US20090304828A1 publication Critical patent/US20090304828A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to pharmaceutical compositions for suppressing and relieving itching and inflammation, as well as functional food that can be used in combination with ethical medicaments to enhance the therapeutic effect thereof without causing side effects.
  • Such itching includes general pruritus which is defined as that is suppressible by commercially available antipruritic drugs such as anti-histamine drugs, and inveterate pruritus, which is defined as that cannot be suppressed by anti-histamine drugs nor by steroid drugs, such as dermal pruritus in hemodialysed patients, senile pruritus, and atopic dermatitis.
  • antipruritic drugs such as anti-histamine drugs
  • inveterate pruritus which is defined as that cannot be suppressed by anti-histamine drugs nor by steroid drugs, such as dermal pruritus in hemodialysed patients, senile pruritus, and atopic dermatitis.
  • the commercially available general antipruritic drugs based on anti-histamine agents are not only ineffective against inveterate pruritus, but also have the drawback of causing side effects such as drowsiness (central inhibition).
  • tacrolimus hydrate ointment an immune suppressor
  • this agent is not well-understood regarding its safeness and it is concerned that the agent may induce skin cancer and induce renal impairment when a significant amount is absorbed from an eroded site of the skin into the body.
  • Patent Document #1 JP2002-338537
  • the present invention is made to solve above problems of the prior art and its main object is to provide a pharmaceutical composition and functional food capable of suppressing and relieving all types of itching including general pruritus and inveterate pruritus safely, as well as inflammation.
  • the present invention provides a pharmaceutical composition containing highly lipophilic polyalkoxyflavonoid extracted from squeezed juice of a whole portion of a citrus fruit, including pericarp thereof.
  • the citrus fruit may be selected from a group consisting of Citrus tachibana, Citrus deliciosa, Citrus kinokuni, Citrus erythrosa, Citrus tangerine, Citrus sunki, Citrus depressa, Citrus tardiva, and Citrus retuculata which belong to Acrumen group, and Citrus hanayu and Citrus calamondin, a dwarf type of citrus cultivated in Southeast Asia, which belong to Osmocitrus group.
  • these pharmaceutical compositions are preferably contained in functional food.
  • the present invention can safely suppress and relieve not only general pruritus but also inveterate pruritus as well as inflammation without causing side effects such as drowsiness, and thus is highly beneficial in preventing, improving, or treating diseases involving cutaneous symptoms.
  • the substance which shows antipruritic and anti-inflammatory effects according to the present invention is the highly lipophilic polyalkoxyflavonoid contained in squeezed juice of a whole portion of a citrus fruit (inclusive of the pericarp thereof).
  • This substance is contained in citrus fruits (inclusive of the pericarp thereof) selected from a group consisting of Citrus tachibana, Citrus deliciosa, Citrus kinokuni, Citrus erythrosa, Citrus tangerina, Citrus sunki, Citrus depressa, Citrus tardiva, and Citrus retuculata which belong to Acrumen group, and Citrus hanayu and Citrus calamondin, a dwarf type of citrus cultivated in Southeast Asia, which belong to Osmocitrus group, and can be readily extracted from the squeezed juice of the whole portion of these fruits.
  • the highly lipophilic polyalkoxyflavonoid of the present invention is included in the pericarp of citrus in a large amount, it is extracted from a solution, which is obtained by mixing the juice from a whole portion of a citrus fruit thereof by press-squeezing or centrifuging, and the pulverized residue of the fruit, by using the known purification techniques. See “Polymethoxylated Flavnoids from the Peels of Citrus depressa” (Yoshihiro Mimaki et al., Natural Medicines, 2000, 54 (6): 351), as needed.
  • the fractionated highly lipophilic polyalkoxyflavonoid is further eluted with lipophilic solvent to obtain eluate containing the highly lipophilic polyalkoxyflavonoid (tangeritin, nobiletine).
  • Powdered preparation can be obtained by spray-drying or freeze-drying of the concentrated eluate.
  • mice were respectively divided into two groups so as that each group contain a desirable number of animals, for example, 12 animals.
  • first group 100 ⁇ L of 10% glycerin solution was uniformly applied to their pruritic site (external use).
  • second group 100 ⁇ l of 10% glycerin solution containing 1% of the substance of the present invention was similarly applied to their corresponding site.
  • Pruritic behaviors such as scratching the pruritic site with teeth or hind legs
  • each animal group were observed and recorded for a predetermined period of time (2 hours) using an overhead video camera with time display, and cumulative time of pruritic behaviors of each group was measured (seconds/120 minutes).
  • the presence or absence of the antipruritic effect in each group was determined using significant difference test based on the cumulative time of the pruritic behaviors. The results were expressed as means ⁇ standard deviations, and Dunnett's t-test was used as the significant difference test.
  • the cumulative time of the pruritic behaviors was 25.50 ⁇ 5.11 (s/120 minutes) in the control group and 17.08 ⁇ 5.26 (s/120 minutes) in the group administered with the substance of the present invention, showing a significant suppressive effect of the substance of the present invention on the pruritus.
  • the cumulative time of the pruritic behaviors was 52.00 ⁇ 7.08 (s/120 minutes) in the control group and 39.33 ⁇ 6.39 (s/120 minutes) in the group administered with the substance of the present invention, showing also a significant antipruritic effect of the substance of the present invention.
  • mice 5 weeks old female ICR mice were divided into two groups each consisting of 12 mice.
  • the first group (the control group) and the second group received 0.3% carboxycellulose (CMC) suspension and 100 mg/kg of the substance of the present invention in 0.3% CMC suspension, respectively, via gavage administration with gastric sound for one week.
  • the animals were allowed to take water and food voluntarily. 8 days after the administration, the mice were passively sensitized by intravenous administration into caudal vein of 0.5 mL monoclonal anti-DNP IgE antibody as antigen to elicit cutaneous reaction.
  • 0.15% DNFB dinitrofluorobenzene; Nakarai Kagaku. Ind.
  • the biphasic dermatitis was 6.33 ⁇ 0.41 ⁇ 10 ⁇ 2 mm and 4.49 ⁇ 0.45 ⁇ 10 ⁇ 2 mm at 1 and 24 hours after the induction, respectively, while in the group administered with the substance of the present invention, the biphasic dermatitis was 4.87 ⁇ 0.50 ⁇ 10 ⁇ 2 mm and 3.47 ⁇ 0.55 ⁇ 10 ⁇ 2 mm at 1 and 24 hours after the induction, respectively, showing a significant anti-inflammatory effect of the substance of the present invention.
  • the pruritic behaviors of the animals were also observed for a predetermined period of time (1 hour) using the above-mentioned video camera with time display.
  • the cumulative time of the pruritic behaviors was 202.17 ⁇ 21.31 (s/60 minutes) and 95.92 ⁇ 24.54 (s/60 minutes) at 1 and 24 hours after the induction, respectively, while in the group administered with the test substance, the cumulative time of the pruritic behaviors was 173.50 ⁇ 22.39 (s/60 minutes) and 72.83 ⁇ 12.83 (s/60 minutes) at 1 and 24 hours after the induction, respectively, showing a significant effect of the substance of the present invention even when being used internally.
  • the biphasic inflammation consisting of immediate hypersensitivity of type I allergy and delayed allergy (type IV allergy), where eosinophil infiltration occurs, was observed.
  • the immediate hypersensitivity corresponds to rhinitis, hay fever, and asthma etc.
  • late allergy corresponds to atopic dermatitis.
  • the inflammation induced by the passive sensitization with IgE antibody and application of DNFB, as well as the accompanying itchiness were significantly suppressed over 24 hours. This shows that the substance of the present invention suppressed and relieved type I allergy, which reached its peak one hour after its induction, and type IV allergy, which reached its peak 24 hours after its induction.
  • the present invention has been found to be effective in suppressing and relieving the symptoms of type I allergic diseases related with immunoglobulin E such as rhinitis, hay fever, and asthma etc., as well as the symptoms of type IV allergic diseases such as atopic dermatitis, which are caused by various antigens such as house dust, pollens, spores, which are inhaled, dietary and alimentary allergens.
  • type IV allergic diseases such as atopic dermatitis, which are caused by various antigens such as house dust, pollens, spores, which are inhaled, dietary and alimentary allergens.
  • the pruritus was biphasic consisting of immediate hypersensitivity (after one hour) corresponding to the histamine-induced pruritus (general pruritus) and delayed type one (after 24 hours) corresponding to kallikrein-induced pruritus (inveterate pruritus).
  • the above evaluation method can be easily used to screen an effective substance which can suppress or relieve the symptoms of type I allergic diseases associated with IgE antibodies at the same time.
  • an effective amount of the highly lipophilic polyalkoxyflavonoid for inhibiting and treating pruritus may be preferably formulated with pharmaceutically acceptable carriers or diluents.
  • Other additives such as binding agents, absorption promoters, lubricants, emulsifiers, surfactants, antioxidants, preservatives, colorants, flavors, sweeteners may be added.
  • the ratio of highly lipophilic polyalkoxyflavonoid, which is the active ingredient, to carriers is at the range of 0.05-30.0 weight %, preferably at the range of 0.1-5.0 weight %.
  • the dosage form of the medicament there can be mentioned such as cataplasm, spray, liquid, suspension, ointment, gel, paste, cream, granules, fine granules, tablet, pill, and capsule.
  • administration routes there can be mentioned various administration routes such as patches, skin application, per os, intravenous, intramuscular, subcutaneous, and administration into a joint cavity, and an external preparation is preferable.
  • the substance of the present invention for skin as the external preparation for skin, the typical components contained in the general products used for skin external preparations can be combined with the substance of the present invention, if needed.
  • the dosage and the dose frequency of the active ingredient can be varied according to the disease condition, age, and sex of a given patient, as well as the administration route.
  • the pharmaceutical composition containing the highly lipophilic polyalkoxyflavonoid of the present invention can be added to various food and beverage products such as snack and soft drink as a functional food for suppressing and relieving itching and inflammation.
  • Functional food is defined as a food which was made to exert sufficient physiological functions (third function) such as biological regulation function, comprising natural products or processed ones thereof including one or more nutrient factors (see “Kenkou/EiyouShokuhin Advisory Staff Textbook, 92-93” published by Daichi Shuppan on Jul. 30, 2003).
  • FIG. 1 is a graph comparing the cumulative time of pruritic behaviors in control group and that in group administered (externally) with the substance of the present invention, each having histamine-induced pruritus.
  • FIG. 2 is a graph comparing the cumulative time of pruritic behaviors in control group and that in group administered (externally) with the substance of the present invention, each having kallikrein-induced pruritus.
  • FIG. 3 is a graph comparing the auricular thickening of control group and that of group administered (internally) with the substance of the present invention.
  • FIG. 4 is a graph comparing the accumulated time of pruritic behaviors of control group and that of group administered (internally) with the substance of the present invention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

It is intended to provide a drug and a functional food by which any itching such as common itching and intractable itching can be safely controlled and relieved and, furthermore, inflammation can be controlled and relieved. A medicine capable of controlling and relieving itching and inflammation which contains a highly lipophilic polyalkoxyflavonoid extracted from a press juice of a whole citrus fruit (a fruit having its peel), and a function food containing this medicine.

Description

    TECHNICAL FIELD
  • The present invention relates to pharmaceutical compositions for suppressing and relieving itching and inflammation, as well as functional food that can be used in combination with ethical medicaments to enhance the therapeutic effect thereof without causing side effects.
    • BACKGROUND ART
  • Most of the cutaneous diseases are generally accompanied by itching. Suppression and relief of such itching are one of the most important tasks in the clinical practice of today, because many dermatologists mention that the aggravation of, for example, atopic dermatitis can be prevented only if the itching can be suppressed.
  • Such itching includes general pruritus which is defined as that is suppressible by commercially available antipruritic drugs such as anti-histamine drugs, and inveterate pruritus, which is defined as that cannot be suppressed by anti-histamine drugs nor by steroid drugs, such as dermal pruritus in hemodialysed patients, senile pruritus, and atopic dermatitis. The commercially available general antipruritic drugs based on anti-histamine agents are not only ineffective against inveterate pruritus, but also have the drawback of causing side effects such as drowsiness (central inhibition).
  • Although tacrolimus hydrate ointment, an immune suppressor, has recently been reported to be effective in treating atopic dermatitis (see Patent Document #1), this agent is not well-understood regarding its safeness and it is concerned that the agent may induce skin cancer and induce renal impairment when a significant amount is absorbed from an eroded site of the skin into the body.
    • Patent Document #1: JP2002-338537 DISCLOSURE OF THE INVENTION Problems to be Solved by the Invention
  • The present invention is made to solve above problems of the prior art and its main object is to provide a pharmaceutical composition and functional food capable of suppressing and relieving all types of itching including general pruritus and inveterate pruritus safely, as well as inflammation.
    • Means for Solving Problems
  • To achieve the object, the present invention provides a pharmaceutical composition containing highly lipophilic polyalkoxyflavonoid extracted from squeezed juice of a whole portion of a citrus fruit, including pericarp thereof. Preferably, the citrus fruit may be selected from a group consisting of Citrus tachibana, Citrus deliciosa, Citrus kinokuni, Citrus erythrosa, Citrus tangerine, Citrus sunki, Citrus depressa, Citrus tardiva, and Citrus retuculata which belong to Acrumen group, and Citrus hanayu and Citrus calamondin, a dwarf type of citrus cultivated in Southeast Asia, which belong to Osmocitrus group. In addition, these pharmaceutical compositions are preferably contained in functional food.
    • EFFECT OF THE INVENTION
  • The present invention can safely suppress and relieve not only general pruritus but also inveterate pruritus as well as inflammation without causing side effects such as drowsiness, and thus is highly beneficial in preventing, improving, or treating diseases involving cutaneous symptoms.
    • PREFERRED EMBODIMENT
  • Now, the present invention is described below in more detail with reference to the attached drawings.
  • The substance which shows antipruritic and anti-inflammatory effects according to the present invention is the highly lipophilic polyalkoxyflavonoid contained in squeezed juice of a whole portion of a citrus fruit (inclusive of the pericarp thereof). This substance is contained in citrus fruits (inclusive of the pericarp thereof) selected from a group consisting of Citrus tachibana, Citrus deliciosa, Citrus kinokuni, Citrus erythrosa, Citrus tangerina, Citrus sunki, Citrus depressa, Citrus tardiva, and Citrus retuculata which belong to Acrumen group, and Citrus hanayu and Citrus calamondin, a dwarf type of citrus cultivated in Southeast Asia, which belong to Osmocitrus group, and can be readily extracted from the squeezed juice of the whole portion of these fruits.
  • Since the highly lipophilic polyalkoxyflavonoid of the present invention is included in the pericarp of citrus in a large amount, it is extracted from a solution, which is obtained by mixing the juice from a whole portion of a citrus fruit thereof by press-squeezing or centrifuging, and the pulverized residue of the fruit, by using the known purification techniques. See “Polymethoxylated Flavnoids from the Peels of Citrus depressa” (Yoshihiro Mimaki et al., Natural Medicines, 2000, 54 (6): 351), as needed.
  • The fractionated highly lipophilic polyalkoxyflavonoid is further eluted with lipophilic solvent to obtain eluate containing the highly lipophilic polyalkoxyflavonoid (tangeritin, nobiletine). Powdered preparation can be obtained by spray-drying or freeze-drying of the concentrated eluate.
    • [Verification of the Antipruritic Effect by External Use]
  • Next, the verification results of the antipruritic effect of the substance of the present invention (highly lipophilic polyalkoxyflavonoid) extracted as above are described.
  • First, general pruritus and inveterate pruritus appearance model animals were induced by using guinea pigs. Specifically, 8 weeks old male Hartley guinea pigs were shaved on the right ventral region with an electric shaver and a shaver 1 day before the experiment. Those to be used as a general pruritus model were intracutaneously administered with histamine hydrochloride (0.3 mg/ml), and those to be used as an inveterate pruritus model were intracutaneously administered with swine spleen kallikrein (25 U/0.05 ml) to induce pruritus. This provided animal models of pruritus that allow evaluation of antipruritic effect on both of general pruritus, which can be suppressed by the conventional antipruritic drugs, and the inveterate pruritus, which cannot be suppressed by the conventional antipruritic drugs (see “Evaluation of antipruritic effect of apple polyphenols using a new animal model of pruritus”, The Journal of Tokyo Medical University, 2002, Vol. 60, No. 2: 123-129,).
  • These animal models were respectively divided into two groups so as that each group contain a desirable number of animals, for example, 12 animals. For the first group (control group), 100 μL of 10% glycerin solution was uniformly applied to their pruritic site (external use). For the second group (test substance group), 100 μl of 10% glycerin solution containing 1% of the substance of the present invention was similarly applied to their corresponding site. Pruritic behaviors (such as scratching the pruritic site with teeth or hind legs) of each animal group were observed and recorded for a predetermined period of time (2 hours) using an overhead video camera with time display, and cumulative time of pruritic behaviors of each group was measured (seconds/120 minutes). The presence or absence of the antipruritic effect in each group was determined using significant difference test based on the cumulative time of the pruritic behaviors. The results were expressed as means±standard deviations, and Dunnett's t-test was used as the significant difference test.
  • As shown in FIG. 1, for the groups having histamine-induced pruritus (the general pruritus), the cumulative time of the pruritic behaviors was 25.50±5.11 (s/120 minutes) in the control group and 17.08±5.26 (s/120 minutes) in the group administered with the substance of the present invention, showing a significant suppressive effect of the substance of the present invention on the pruritus.
  • In addition, as shown in FIG. 2, for the groups having kallikrein-induced pruritus (inveterate pruritus), the cumulative time of the pruritic behaviors was 52.00±7.08 (s/120 minutes) in the control group and 39.33±6.39 (s/120 minutes) in the group administered with the substance of the present invention, showing also a significant antipruritic effect of the substance of the present invention.
  • Thus, these results show that the substance of the present invention with a sufficient concentration of 1% or more provides an antipruritic effect not only on histamine-induced pruritus but also on kallikrein-induced pruritus, which cannot be suppressed by the anti-histamine drugs at all, with the same effectiveness.
    • [Verification of the Anti-Inflammatory Effect by Internal Use]
  • Next, the anti-inflammatory effect of the substance of the present invention by internal use was verified.
  • 5 weeks old female ICR mice were divided into two groups each consisting of 12 mice. The first group (the control group) and the second group received 0.3% carboxycellulose (CMC) suspension and 100 mg/kg of the substance of the present invention in 0.3% CMC suspension, respectively, via gavage administration with gastric sound for one week. The animals were allowed to take water and food voluntarily. 8 days after the administration, the mice were passively sensitized by intravenous administration into caudal vein of 0.5 mL monoclonal anti-DNP IgE antibody as antigen to elicit cutaneous reaction. One hour after the elicitation, 0.15% DNFB (dinitrofluorobenzene; Nakarai Kagaku. Ind. Co., Japan) solution prepared with acetone-olive oil (4:1) was applied to the auricle of the animals to induce dermatitis. At 1, 4, 24, and 48 hours after the induction of dermatitis, auricular thickening which indicates the degree of dermatitis was measured for each group using Dial Thickness Gauge (Mitsutoyo Corporation, Kanagawa, Japan).
  • As shown in FIG. 3, in the control group, the biphasic dermatitis was 6.33±0.41×10−2 mm and 4.49±0.45×10−2 mm at 1 and 24 hours after the induction, respectively, while in the group administered with the substance of the present invention, the biphasic dermatitis was 4.87±0.50×10−2 mm and 3.47±0.55×10−2 mm at 1 and 24 hours after the induction, respectively, showing a significant anti-inflammatory effect of the substance of the present invention.
    • [Verification of the Antipruritic Effect by the Internal Use]
  • In parallel with auricular thickening measurement, the pruritic behaviors of the animals were also observed for a predetermined period of time (1 hour) using the above-mentioned video camera with time display. As shown in the FIG. 4, in the control group, the cumulative time of the pruritic behaviors was 202.17±21.31 (s/60 minutes) and 95.92±24.54 (s/60 minutes) at 1 and 24 hours after the induction, respectively, while in the group administered with the test substance, the cumulative time of the pruritic behaviors was 173.50±22.39 (s/60 minutes) and 72.83±12.83 (s/60 minutes) at 1 and 24 hours after the induction, respectively, showing a significant effect of the substance of the present invention even when being used internally.
  • In the cutaneous reaction of the mice passively sensitized with IgE antibody, the biphasic inflammation consisting of immediate hypersensitivity of type I allergy and delayed allergy (type IV allergy), where eosinophil infiltration occurs, was observed. The immediate hypersensitivity corresponds to rhinitis, hay fever, and asthma etc., while late allergy corresponds to atopic dermatitis. Namely, compared to the control mice group, which didn't receive the substance of the present invention, in the mice group previously administered with the substance of the present invention, the inflammation induced by the passive sensitization with IgE antibody and application of DNFB, as well as the accompanying itchiness were significantly suppressed over 24 hours. This shows that the substance of the present invention suppressed and relieved type I allergy, which reached its peak one hour after its induction, and type IV allergy, which reached its peak 24 hours after its induction.
  • Therefore, the present invention has been found to be effective in suppressing and relieving the symptoms of type I allergic diseases related with immunoglobulin E such as rhinitis, hay fever, and asthma etc., as well as the symptoms of type IV allergic diseases such as atopic dermatitis, which are caused by various antigens such as house dust, pollens, spores, which are inhaled, dietary and alimentary allergens. In addition, the pruritus was biphasic consisting of immediate hypersensitivity (after one hour) corresponding to the histamine-induced pruritus (general pruritus) and delayed type one (after 24 hours) corresponding to kallikrein-induced pruritus (inveterate pruritus).
  • The above evaluation method can be easily used to screen an effective substance which can suppress or relieve the symptoms of type I allergic diseases associated with IgE antibodies at the same time. For the detail of this method, see Pharmacometrics, Vol. 69, No. 1/2, 47-51 published on Oct. 1, 2005.
  • On using the highly lipophilic polyalkoxyflavonoid of the present invention as a medicament, an effective amount of the highly lipophilic polyalkoxyflavonoid for inhibiting and treating pruritus may be preferably formulated with pharmaceutically acceptable carriers or diluents. Other additives such as binding agents, absorption promoters, lubricants, emulsifiers, surfactants, antioxidants, preservatives, colorants, flavors, sweeteners may be added.
  • In such formulation, the ratio of highly lipophilic polyalkoxyflavonoid, which is the active ingredient, to carriers is at the range of 0.05-30.0 weight %, preferably at the range of 0.1-5.0 weight %.
  • As the dosage form of the medicament, there can be mentioned such as cataplasm, spray, liquid, suspension, ointment, gel, paste, cream, granules, fine granules, tablet, pill, and capsule. As their administration routes, there can be mentioned various administration routes such as patches, skin application, per os, intravenous, intramuscular, subcutaneous, and administration into a joint cavity, and an external preparation is preferable. In case of using the substance of the present invention for skin as the external preparation for skin, the typical components contained in the general products used for skin external preparations can be combined with the substance of the present invention, if needed. In addition, the dosage and the dose frequency of the active ingredient can be varied according to the disease condition, age, and sex of a given patient, as well as the administration route.
  • The pharmaceutical composition containing the highly lipophilic polyalkoxyflavonoid of the present invention can be added to various food and beverage products such as snack and soft drink as a functional food for suppressing and relieving itching and inflammation. Functional food is defined as a food which was made to exert sufficient physiological functions (third function) such as biological regulation function, comprising natural products or processed ones thereof including one or more nutrient factors (see “Kenkou/EiyouShokuhin Advisory Staff Textbook, 92-93” published by Daichi Shuppan on Jul. 30, 2003).
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a graph comparing the cumulative time of pruritic behaviors in control group and that in group administered (externally) with the substance of the present invention, each having histamine-induced pruritus.
  • FIG. 2 is a graph comparing the cumulative time of pruritic behaviors in control group and that in group administered (externally) with the substance of the present invention, each having kallikrein-induced pruritus.
  • FIG. 3 is a graph comparing the auricular thickening of control group and that of group administered (internally) with the substance of the present invention.
  • FIG. 4 is a graph comparing the accumulated time of pruritic behaviors of control group and that of group administered (internally) with the substance of the present invention.

Claims (4)

1. A pharmaceutical composition for suppressing and relieving itching and inflammation, comprising highly lipophilic polyalkoxyflavonoid extracted from squeezed juice of a whole portion of a citrus fruit, including pericarp thereof.
2. The pharmaceutical composition according to claim 1, wherein said citrus fruit is selected from a group consisting of Citrus tachibana, Citrus deliciosa, Citrus kinokuni, Citrus erythrosa, Citrus tangerina, Citrus sunki, Citrus depressa, Citrus tardiva, and Citrus retuculata which belong to Acrumen group, and Citrus hanayu and Citrus calamondin, a dwarf type of citrus cultivated in Southeast Asia, which belong to Osmocitrus group.
3. A functional food for suppressing and relieving itching and inflammation, comprising the pharmaceutical composition according to claim 1.
4. A functional food for suppressing and relieving itching and inflammation, comprising the pharmaceutical composition according to claim 2.
US12/224,193 2006-02-22 2007-02-19 Pharmaceutical Composition and Functional Food for Suppressing and Relieving Itching and Inflammation Abandoned US20090304828A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006-044801 2006-02-22
JP2006044801 2006-02-22
PCT/JP2007/052978 WO2007097286A1 (en) 2006-02-22 2007-02-19 Medicine and functional food for controlling or relieving itching and inflammation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/052978 A-371-Of-International WO2007097286A1 (en) 2006-02-22 2007-02-19 Medicine and functional food for controlling or relieving itching and inflammation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/371,085 Division US8889198B2 (en) 2006-02-22 2012-02-10 Method for suppressing and relieving itching and inflammation

Publications (1)

Publication Number Publication Date
US20090304828A1 true US20090304828A1 (en) 2009-12-10

Family

ID=38437326

Family Applications (3)

Application Number Title Priority Date Filing Date
US12/224,193 Abandoned US20090304828A1 (en) 2006-02-22 2007-02-19 Pharmaceutical Composition and Functional Food for Suppressing and Relieving Itching and Inflammation
US13/371,085 Active 2027-10-19 US8889198B2 (en) 2006-02-22 2012-02-10 Method for suppressing and relieving itching and inflammation
US14/517,818 Active US9017739B2 (en) 2006-02-22 2014-10-18 Method for suppressing and relieving itching and inflammation

Family Applications After (2)

Application Number Title Priority Date Filing Date
US13/371,085 Active 2027-10-19 US8889198B2 (en) 2006-02-22 2012-02-10 Method for suppressing and relieving itching and inflammation
US14/517,818 Active US9017739B2 (en) 2006-02-22 2014-10-18 Method for suppressing and relieving itching and inflammation

Country Status (7)

Country Link
US (3) US20090304828A1 (en)
EP (1) EP1987826B1 (en)
JP (1) JP4819869B2 (en)
KR (1) KR101430509B1 (en)
AU (1) AU2007218779B2 (en)
CA (1) CA2643270C (en)
WO (1) WO2007097286A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2943535B1 (en) * 2009-03-31 2011-08-12 Lvmh Rech NEW USE OF A PLANT EXTRACT OBTAINED FROM AT LEAST ONE PLANT BELONGING TO THE GENUS CITRUS, OR A HYBRID FROM THE CROSSING OF VEGETABLE SPECIES OF WHICH AT LEAST ONE APPEARS TO THE GENUS CITRUS.
US9801404B2 (en) 2012-12-26 2017-10-31 Morinaga Milk Industry Co., Ltd. IGF-1 production-promoting agent
KR101677083B1 (en) * 2014-11-10 2016-11-17 대한민국 Anti-inflammatory active composition and pharmaceutical composition comprising the same
KR101629706B1 (en) * 2015-09-08 2016-06-13 (주)셀트리온 Composition containing natural plant extract for alleviating inflammation by yellow sand and fine dust
CN118021910A (en) * 2019-08-23 2024-05-14 太康海恩药业有限公司 Application of antipruritic composition in preparation of medicine for treating pruritus symptom

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07118151A (en) * 1993-10-21 1995-05-09 Kureha Chem Ind Co Ltd Therapeutic agent for atopic dermatitis
JP2001240539A (en) * 2000-03-02 2001-09-04 Machida & Machida Shokai:Kk Drug or functional foods for control elevation of blood pressure or blood sugar
JP2002338537A (en) 2001-05-16 2002-11-27 Mitsubishi Pharma Corp Amide compound and its medicinal use
JP2003192588A (en) * 2001-12-27 2003-07-09 National Agricultural Research Organization Uv-induced prostaglandin e2 production suppressing agent
JP2004083417A (en) * 2002-08-22 2004-03-18 National Agriculture & Bio-Oriented Research Organization Vascularization inhibitor
DE10240923A1 (en) * 2002-09-02 2004-03-04 Merck Patent Gmbh Flavonoid derivatives for eczema treatment
JP2005213178A (en) * 2004-01-29 2005-08-11 Maruzen Pharmaceut Co Ltd TNF-alpha PRODUCTION INHIBITOR, ESTROGENIC AGENT AND EXTERNAL PREPARATION FOR SKIN
JP2005336070A (en) * 2004-05-25 2005-12-08 Sanei Gen Ffi Inc MASTOCYTE IgE RECEPTOR EXPRESSION INHIBITORY SUBSTANCE, AND COMPOSITION CONTAINING THE SAME
JP2006348003A (en) * 2005-06-20 2006-12-28 Sanei Gen Ffi Inc Mastocyte ige receptor expression inhibitor

Also Published As

Publication number Publication date
US20150037440A1 (en) 2015-02-05
CA2643270A1 (en) 2007-08-30
WO2007097286A1 (en) 2007-08-30
US9017739B2 (en) 2015-04-28
EP1987826B1 (en) 2015-05-27
AU2007218779B2 (en) 2012-12-20
US8889198B2 (en) 2014-11-18
CA2643270C (en) 2014-07-15
KR101430509B1 (en) 2014-08-18
EP1987826A1 (en) 2008-11-05
EP1987826A8 (en) 2009-03-18
EP1987826A4 (en) 2011-08-03
JP4819869B2 (en) 2011-11-24
JPWO2007097286A1 (en) 2009-07-16
AU2007218779A1 (en) 2007-08-30
KR20090007281A (en) 2009-01-16
US20120141615A1 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
Poli et al. Nutraceuticals and functional foods for the control of plasma cholesterol levels. An intersociety position paper
US9017739B2 (en) Method for suppressing and relieving itching and inflammation
WO2014162925A1 (en) Composition for preventing joint aging
KR20100117074A (en) Composition containing capsicum for treating a skin disorder
CA2807520A1 (en) Soybean extracts for the treatment of hepatic disorders
JP2003088329A (en) Analgesic health supplement
JPWO2009142320A1 (en) Atopic dermatitis preventive and / or therapeutic agent
Chang et al. Treatment of eczema
US20080175888A1 (en) Combination Therapy Comprising Actinidia and Steroids and Uses Thereof
JP2018530319A (en) Combined composition for blood glucose control, liver protection, and prevention and treatment of related medical conditions
JP4325908B2 (en) Lipolysis accelerator, skin external preparation and food and drink using the same
Stengler The Natural Physician's Healing Therapies: Proven Remedies Medical Doctors Don't Know
JP2015218145A (en) TNF-α PRODUCTION INHIBITOR
JP2007031302A (en) Adiponectin production accelerator and metabolic syndrome preventive
JP2003313138A (en) Medicament or functional food for suppressing pruritus, and method for evaluating the effect
WO2006091804A2 (en) Compositions and methods for the treatment of acne
JP2008133292A (en) Medicine for suppressing itching
JP2005015414A (en) Medicine or functional food for suppressing/relieving symptom of allergic disease
JP4221266B2 (en) Drugs for suppressing or alleviating symptoms of allergic diseases
JP4221267B2 (en) Drugs to suppress itching
JP2002173434A (en) Antiallergic composition
JP3857965B2 (en) External preparations to suppress itch
KR20160055135A (en) Methods for reducing the occurrence of hot flashes
Chauhan et al. Management of allergic contact dermatitis with Ayurvedic intervention
Willix The Rejuvenation Solution: Age in Reverse--7 Proven Medical Breakthroughs That Prevent Disease and Make You Feel Years Younger

Legal Events

Date Code Title Description
AS Assignment

Owner name: ERINA CO., INC., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TAGUCHI, KAZUE;TAGUCHI, SHIGERU;SASHIDA, YUTAKA;REEL/FRAME:023350/0522

Effective date: 20081206

Owner name: KANDS R&D CORPORATION, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TAGUCHI, KAZUE;TAGUCHI, SHIGERU;SASHIDA, YUTAKA;REEL/FRAME:023350/0522

Effective date: 20081206

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION